1. 27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. Issue 3 (September 2015) Authors: Arkenau, H.T.; Voskoboynik, M.; Infante, J.; Brenner, A.; Patel, M.; Borazanci, E.; Falchook, G.; Molife, L.R.; Pant, S.; Dean, E.; Pelosof, L.; Jones, S.; Rubino, C.; McCulloch, W.; Zhukova-Harrill, V.; Kemble, G.; O'Farrell, M.; Burris, H. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗